Industry Newsgene therapybiotechuniqureanalyst ratings
UniQure Receives Analyst Coverage And Buy Rating
6.1
UniQure received fresh analyst attention in February 2026 as Wolfe Research initiated coverage with a Peer Perform rating on Feb. 23 and H.C. Wainwright reiterated a Buy on Feb. 10 with a $70 price target. H.C. Wainwright cited new Fabry disease gene-therapy data and a manageable safety profile that refine dosing, while noting no near-term regulatory catalysts but added longer-term value.
Key Points
- 1Wolfe Research initiates coverage with Peer Perform rating on Feb 23
- 2H.C. Wainwright reiterates Buy, sets $70 target citing Fabry disease data and manageable safety
- 3Signals valuation impact: data and CNS progress add long-term value, but no near-term regulatory catalysts
Scoring Rationale
Analyst updates and supportive clinical data drive relevance, limited by narrow biotech focus and lack of near-term regulatory catalysts.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems